![Douglas Kling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 296 418 $ au 31/05/2026
Douglas F.
Kling currently works at NewAmsterdam Pharma BV, as Chief Operating Officer from 2021, NewAmsterdam Pharma Holding BV, as Chief Operating Officer from 2021, and NewAmsterdam Pharma Co. NV, as Chief Operating Officer from 2021.
Mr. Kling also formerly worked at The Medicines Co., as Senior Director-Program Management from 2008 to 2009, Reliant Pharmaceuticals LLC, as Director-R&D Project Management from 2000 to 2008, Shionogi USA Holdings, Inc., as Senior Director-Project Management from 2009 to 2010, Omthera Pharmaceuticals, Inc., as Senior Vice President-Clinical Development from 2010 to 2014, Matinas BioPharma Holdings, Inc., as SVP-Clinical Development & Project Management from 2015 to 2017, Knoll Pharmaceutical Co., as Manager-Clinical Research from 1998 to 2000, and Corvidia Therapeutics, Inc., as Senior Vice President-Clinical Operations from 2017 to 2021.
Mr. Kling received his undergraduate degree from Duke University and Masters Business Admin degree from Rutgers Business School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2026 | 8 801 ( 0,01 % ) | 296 418 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Directeur des opérations | 01/03/2021 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Directeur des opérations | 01/03/2021 |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Directeur des opérations | 01/03/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Develops precision cardiovascular therapies | Corporate Officer/Principal | 01/02/2021 |
| MATINAS BIOPHARMA HOLDINGS, INC. | Corporate Officer/Principal | 01/11/2017 |
Omthera Pharmaceuticals, Inc.
 Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia | Corporate Officer/Principal | 01/12/2014 |
Shionogi USA Holdings, Inc. | Corporate Officer/Principal | 01/07/2010 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01/07/2009 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 12 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Reliant Pharmaceuticals LLC
 Reliant Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia | Health Technology |
Matinas BioPharma Holdings, Inc.
 Matinas BioPharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Knoll Pharmaceutical Co. | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Health Technology |
Rutgers Business School
 Rutgers Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shionogi USA Holdings, Inc. | |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Develops precision cardiovascular therapies | Health Technology |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Health Technology |
NewAmsterdam Pharma Co. NV
 NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
